H
Hanno Wild
Researcher at Bayer Corporation
Publications - 18
Citations - 281
Hanno Wild is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Open innovation & Trifluoromethyl. The author has an hindex of 9, co-authored 18 publications receiving 274 citations. Previous affiliations of Hanno Wild include Bayer.
Papers
More filters
Journal ArticleDOI
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.
Tobias Wunberg,Martin Hendrix,Alexander Hillisch,Mario Lobell,Heinrich Meier,Carsten Schmeck,Hanno Wild,Berthold Hinzen +7 more
TL;DR: This work describes how to break down large numbers of screening hits and provides a comprehensive overview of the strengths and weaknesses for each structural class.
Patent
4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hif-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases
Flamme Ingo,Erguden Jens-Kerim,Felix Oehme,Kai Thede,Gunter Karig,Alexander Kuhl,Hanno Wild,Joachim Schuhmacher,Kolkhof Peter,Baerfacker Lars,Huetter Joachim +10 more
TL;DR: In this paper, the authors present an application related to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases, and their use in the preparation of medicaments for treatment or prevention of diseases.
Journal ArticleDOI
One target-multiple indications: a call for an integrated common mechanisms strategy.
TL;DR: This article proposes to systematically evaluate the full therapeutic potential of a drug target, proprietary chemical lead structure, or drug candidate as broad and as early as possible and calls this the 'common mechanism' approach.
Journal ArticleDOI
Editorial: The Importance of Chemistry for the Future of the Pharma Industry
Patent
Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors
Kai Thede,Flamme Ingo,Felix Oehme,Erguden Jens-Kerim,Friederike Stoll,Joachim Schuhmacher,Hanno Wild,Kolkhof Peter,Beck Hartmut,Akbaba Metin,Jeske Mario +10 more
TL;DR: In this paper, substituted dihydropyrazolon-derivatives are used for treating and/or preventing diseases, in particular cardiovascular and haematological diseases, kidney diseases and for promoting the healing of wounds.